Tolerance of "on Line" Hemodiafiltration in Chronic Renal Failure Patients

Tolerance of "on Line" Hemodiafiltration and Impact on Morbidity and Cardiovascular Risk Factors in Chronic Renal Failure Patients

The aim of this study is to appreciate the tolerance of "on line" hemodiafiltration and its impact on morbidity and cardiovascular risk factors in chronic renal failure patient.

The aim of this study is to appreciate the tolerance of "on line" HDF treatment versus conventional high flux hemodialysis in term of adverse events occuring during dialysis sessions between day 30 and day 120 of treatment and to evaluate:

• Quality of life evaluated with the KDQOL questionnaire
• Incidence of cardiovascular events
• Influence of the technic on cardiovascular, inflammatory and infectious risk factors
• Mortality

Inclusion Criteria:

• Patient who has signed the written consent form
• Patient aged > 65 and < 90 years
• With creatinine clearance < 10 mL/min
• On dialysis for a minimum of 3 months, with 3 times a week hemodialysis sessions
• Erythropoietin dosage needed to maintain hemoglobin at a constant level (range of hemoglobin: 9-13 g/dL without any variation of more than 2g/dL for less than 3 months)
• Without any problem of vascular access

Exclusion Criteria:

• Patient aged < 65 and > 90 years
• Presence of severe malnutrition (albumin < 20 g/L)
• Unstable clinical condition
• Unipuncture or failed vascular access flow
• Known problems of coagulation